SEC Filing Analysis: OKYO Pharma Ltd

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Dauntless Investment Group, LLC, a passive institutional investor, has filed an amendment to its Schedule 13G, reporting a beneficial ownership stake of 2,422,048 shares, or 6.3% of OKYO Pharma Ltd.
• Market Impact: Neutral. This filing confirms a continued, significant holding rather than a new transaction, providing a sign of stability but not necessarily a catalyst for immediate price movement.

Company Information

Field	Value
Company	OKYO Pharma Ltd
Ticker Symbol	Not specified in filing
CIK	0001849296
Industry	Biological Products

Filer Information

Field	Value
Name	Dauntless Investment Group, LLC
CIK	0002044285
Type	Passive Investor (Single Family Office)
Relationship	Beneficial Owner (>5%)

Holding Details

Field	Value
Form Type	SCHEDULE 13G/A (Amendment No. 2)
Event Date	2025-09-30
Security Type	Common
Shares Owned	2,422,048
Ownership Percentage	6.3%

Financial Impact Assessment

Holding Materiality

Metric	Value
Holding Value (Est.)	~$6,440,000
% of Market Cap	6.44%
Shares Held	2,422,048
% of Shares Outstanding	6.44%
Materiality Assessment	The holding is significant, representing a substantial portion of the company's total equity and market value.

Impact Evaluation

• Market Cap Context: For a small-cap company with a market capitalization of $100 million, a single institutional holding valued at approximately $6.44 million is a material position that makes the filer a key stakeholder.
• Ownership Concentration: A 6.44% stake demonstrates a notable concentration of ownership. While filed as a passive investment, the size of the holding gives the investor a significant voice. Any future liquidation of this position could exert considerable pressure on the stock price.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is Amendment No. 2 to a Schedule 13G, indicating an update to an existing position rather than a new accumulation or sale. As such, it confirms the status quo of a large institutional holder and is unlikely to be a primary driver of price action.

Volume & Sentiment

• Expected Volume Impact: Low. Position filings typically do not drive significant trading volume unless they reveal a major, unexpected change in ownership.
• Sentiment Indicator: Neutral. The filing is a procedural update that confirms continued institutional conviction, which can be viewed as mildly positive, but it does not signal new buying activity.

Investment Insights

Positive Market Indicators

• Institutional Conviction: The continued holding of a significant stake by an institutional investor in a small-cap biotech company can be seen as a vote of confidence.
• Passive Stake: The filing under Rule 13d-1(c) certifies that the shares were not acquired for the purpose of changing or influencing control of the company, reducing the risk of an activist campaign.

Risk Factors

• Ownership Concentration: A large, concentrated holding poses a risk of a stock overhang. If Dauntless Investment Group decides to sell its position in the future, it could create significant downward pressure on the stock price due to the size of the stake relative to the company's market cap.

Key Takeaways

1. Dauntless Investment Group remains a major shareholder in OKYO Pharma with a 6.3% stake.
2. The holding is valued at approximately $6.44 million, representing 6.44% of the company's $100 million market cap.
3. The filing is a passive investment statement, not an activist one, and serves as a confirmation of an existing position.